314 related articles for article (PubMed ID: 33160073)
1. First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers.
Komdeur FL; Singh A; van de Wall S; Meulenberg JJM; Boerma A; Hoogeboom BN; Paijens ST; Oyarce C; de Bruyn M; Schuuring E; Regts J; Marra R; Werner N; Sluis J; van der Zee AGJ; Wilschut JC; Allersma DP; van Zanten CJ; Kosterink JGW; Jorritsma-Smit A; Yigit R; Nijman HW; Daemen T
Mol Ther; 2021 Feb; 29(2):611-625. PubMed ID: 33160073
[TBL] [Abstract][Full Text] [Related]
2. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
4. GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles.
Jorritsma-Smit A; van Zanten CJ; Schoemaker J; Meulenberg JJM; Touw DJ; Kosterink JGW; Nijman HW; Daemen T; Allersma DP
Eur J Pharm Sci; 2020 Feb; 143():105096. PubMed ID: 31669389
[TBL] [Abstract][Full Text] [Related]
5. Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system.
Walczak M; Regts J; van Oosterhout AJ; Boon L; Wilschut J; Nijman HW; Daemen T
Antivir Ther; 2011; 16(2):207-18. PubMed ID: 21447870
[TBL] [Abstract][Full Text] [Related]
6. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
7. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
Daemen T; Regts J; Holtrop M; Wilschut J
Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
[TBL] [Abstract][Full Text] [Related]
8. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
9. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
10. Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.
Ip PP; Boerma A; Walczak M; Oosterhuis K; Haanen JB; Schumacher TN; Nijman HW; Daemen T
Gene Ther; 2015 Jul; 22(7):560-7. PubMed ID: 25756550
[TBL] [Abstract][Full Text] [Related]
11. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.
Draghiciu O; Walczak M; Hoogeboom BN; Franken KL; Melief KJ; Nijman HW; Daemen T
Int J Cancer; 2014 Feb; 134(4):859-72. PubMed ID: 23922012
[TBL] [Abstract][Full Text] [Related]
13. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
[TBL] [Abstract][Full Text] [Related]
14. A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC).
Chandra J; Woo WP; Finlayson N; Liu HY; McGrath M; Ladwa R; Brauer M; Xu Y; Hanson S; Panizza B; Frazer IH; Porceddu SV
Cancer Immunol Immunother; 2021 Mar; 70(3):743-753. PubMed ID: 32918586
[TBL] [Abstract][Full Text] [Related]
15. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
16. Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X.
Illiano E; Bissa M; Paolini F; Zanotto C; De Giuli Morghen C; Franconi R; Radaelli A; Venuti A
Virus Res; 2016 Oct; 225():82-90. PubMed ID: 27664839
[TBL] [Abstract][Full Text] [Related]
17. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses.
Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR
Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864
[TBL] [Abstract][Full Text] [Related]
18. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
19. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
20. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
